Alphatec maintained at outperform by RBC

RBC Capital Markets analyst Phil Nalbone kept Alphatec Holdings Inc. at its outperform, above average risk rating as third-quarter revenue increased 51% from the prior year quarter to $17.4 million. Alphatec management expects fourth-quarter revenue to come in at $17.2 million (+11%). The completion of the Scient'X acquisition has been delayed due to Alphatec's depressed stock price. Nalbone lowered his 12-month price target by $5 to $8. Shares of the Carlsbad, Calif.-based medical device company were down 9 cents, or 2.80%, at $3.12. Nasdaq: ATEC)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.